This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Valeant Pharmaceuticals International, Inc.
Drug Names(s): bexarotene gel, LGD1069
Description: BioMedTracker has separate entries for Targretin capsules and gel. For additional information, please see Targretin capsules.
Targretin consists of bexarotene, a retinoid that selectively activate retinoid X receptors (RXRs). RXRs regulate numerous cell activities including cell cycling, proliferation, and apoptosis.
Ferrer and Ligand
In March 1999, Ligand signed marketing and distribution agreements with Ferrer Internacional, S.A. to exclusively market and distribute ONTAK, Panretin gel, Panretin capsules, Targretin gel and Targretin capsules, in Spain, Portugal, Greece, and Central and South America.
Alfa Wassermann and Ligand
In January 2000, Ligand signed a marketing and distribution agreement with Alfa Wassermann S.p.A. to exclusively market and distribute in Italy ONTAK, Panretin gel, Panretin capsules, Targretin gel and Targretin capsules. Ligand received from Alfa Wassermann, as reimbursement for certain registration services previously incurred by Ligand for the products, $0.75 million upon signing and will receive additional amounts aggregating up to $1.0 million upon achievement of certain milestones. Under the terms of the agreement, Alfa Wassermann will have exclusive long-term marketing and distribution rights and responsibilities in Italy for ONTAK, Panretin...See full deal structure in Biomedtracker
Partners: Grupo Ferrer Internacional, S.A. Perrigo Company PLC Alfa Wassermann SpA Teva Pharmaceutical Industries Ltd. Minophagen Pharmaceutical Co., Ltd. Eisai Co., Ltd.
Targretin gel News
Pink Sheet Targretin Gel 1% FDA Reviewers
Pink Sheet Targretin Gel 1% Clinical Development
Pink Sheet Targretin Gel 1% Clinical Protocols
Additional information available to subscribers only: